Renee McDougal
Family · Carmel, INNPI 1528699576
Payments from drug & device makers
Across 404 payments — averaging $15.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- AbbVie$1K
- Corium, LLC$644
- Supernus Pharmaceuticals, Inc.$491
- Neos Therapeutics, LP$270
- Otsuka America Pharmaceutical, Inc.$242
- plus $2K from 17 others
What the payments were for
- Food & beverage$6,08199%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 80 | $1,852 |
| AbbVie | 68 | $1,085 |
| Corium, LLC | 37 | $644 |
| Supernus Pharmaceuticals, Inc. | 81 | $491 |
| Neos Therapeutics, LP | 19 | $270 |
| Otsuka America Pharmaceutical, Inc. | 15 | $242 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $237 |
| Bausch Health US, LLC | 29 | $226 |
| Ironshore Pharmaceuticals Inc. | 14 | $218 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $180 |
| Axsome Therapeutics, Inc. | 6 | $140 |
| Noven Therapeutics, LLC | 4 | $85 |
| Collegium Pharmaceutical, Inc. | 4 | $81 |
| Tris Pharma Inc | 4 | $78 |
| Merck | 4 | $59 |
| Alkermes, Inc. | 4 | $58 |
| Adlon Therapeutics L.p. | 3 | $47 |
| Eisai Inc. | 2 | $38 |
| Vanda Pharmaceuticals Inc. | 1 | $27 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Lundbeck LLC | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,128 in reported general payments places this provider in the 90th percentile of 4,392 family providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ConcertaMethylphenidate Hcl | 22 | $9,233 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 11 | $285 |
| Alprazolam | 11 | $145 |
| Clonazepam | 13 | $2 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonConcerta | $1,852 | $9,23322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,392 family providers in Indiana.
Other family in Carmel
- Rachel LytleCarmel$13K
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
- Myra SikwataHobart$131K
- Elizabeth JohnsonEvansville$108K
- Beverly MaugerFt Wayne$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.